Pharmabiz6h
ABL Bio enters Grabody-B brain delivery platform license pact with GSK to develop novel medicines for neurodegenerative diseases
ABL Bio enters Grabody-B brain delivery platform license pact with GSK to develop novel medicines for neurodegenerative diseases: Seongnam, South Korea Tuesday, April 8, 2025, 17: ...
Manila Bulletin1d
How this dermal filler can make you feel forever young
A groundbreaking collagen-based dermal filler has officially launched in the Philippines, promising a new approach to facial ...
Contract Pharma6h
ABL Bio and GSK to Develop Medicines for Neurodegenerative Diseases
Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.
GSK targets neurodegenerative diseases with latest licensing deal
The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...
The Pharma Letter1d
ABL Bio leaps as it announces deal with GSK
South Korean clinical-stage biotech ABL Bio (Kosdaq: 298380) on Sunday announced a worldwide licensing agreement enabling GSK ...
PMLive1d
GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn
GSK and ABL Bio have entered into an agreement worth over £2bn to develop new drugs for neurodegenerative diseases.
Frontiers3d
Mitochondrial MicroRNAs Contribute to Macrophage Immune Functions Including Differentiation, Polarization, and Activation
A subset of microRNA (miRNA) has been shown to play an important role in mitochondrial (mt) functions and are named MitomiR. They are present within or associated with mitochondria. Most of the ...